Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kinetics

Authors :: Shinya Hamasu
Dai Manaka
Y. Nishikawa
H. An
Sayuri Konishi
K. Kawaguchi
T. Ota
Ryuta Nishitai
Ryo Kudo
Source :: Annals of Oncology. 29:v63
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Chemotherapy
biology
Cetuximab
Colorectal cancer
business.industry
medicine.medical_treatment
Hematology
medicine.disease
Oncology
medicine
biology.protein
Cancer research
Panitumumab
Antibody
Neutrophil to lymphocyte ratio
business
medicine.drug

Full Text Access

Tools